Pasithea Therapeutics Gains FDA Orphan Drug Designation for PAS-004 in ALS

For development teams tracking rare disease pipelines, Pasithea Therapeutics' FDA Orphan Drug Designation for PAS-004 in ALS signals a meaningful shift in the compound's regulatory posture, one that unlocks a defined set of incentives with direct implications for clinical manufacturing planning and cost structure.

The FDA granted the designation for PAS-004, Pasithea's macrocyclic MEK inhibitor, covering the treatment of Amyotrophic Lateral Sclerosis, a progressive neurodegenerative disease affecting motor neurons in the brain and spinal cord. ALS meets the statutory threshold for Orphan Drug Designation: fewer than 200,000 patients in the United States, with no curative options and a median survival of two to five years post-diagnosis.

The designation carries three operationally relevant benefits: eligibility for tax credits on qualified clinical trial costs, exemption from certain FDA user fees, and the potential for seven years of post-approval market exclusivity. For a clinical-stage company managing capital allocation across multiple programs, the fee exemptions and tax offsets reduce the cost burden of advancing through Phase 1 and into later-stage manufacturing readiness.

Pasithea is currently running two active Phase 1 studies for PAS-004, one in advanced cancer (NCT06299839) and a Phase 1/1b in neurofibromatosis type 1-associated plexiform neurofibromas (NCT06961565). The ALS designation does not alter those trial protocols but positions the company to pursue a parallel development track, supported in part by a $1 million grant awarded by the ALS Association in November 2025 to study PAS-004's efficacy, safety, and tolerability in ALS patients.

The mechanistic rationale centers on MAPK pathway dysregulation. Pasithea's CEO, Dr. Tiago Reis Marques, cited the role of MAPK signaling in ALS pathology as the scientific basis for exploring PAS-004 in this indication, consistent with the compound's broader positioning across RASopathies and MAPK-driven disease states. For QA and regulatory leads, the cross-indication strategy raises process validation considerations: any future ALS-specific formulation or dosing regimen would require bridging data and potentially distinct CMC documentation under 21 CFR Part 211.

The seven-year exclusivity window, contingent on approval, gives Pasithea a defined commercial protection horizon, but the more immediate operational consequence is the reduction in regulatory friction during the IND and NDA phases, where orphan status streamlines certain FDA interactions.

The ALS Association grant timeline and Phase 1 data readouts from the oncology and NF1 trials will serve as the near-term indicators of whether PAS-004's MAPK inhibition profile translates into a viable ALS development pathway.

Source: Pasithea Therapeutics Corp. via GlobeNewswire, June 2, 2026.